COVID-19: Back-to-Work

COVID Testing Industry Consortium

The global impact of COVID-19, the disease caused by SARS-CoV-2, is overwhelming. The numbers of people whose lives have been impacted, positive cases, hospitalizations, admissions to ICU’s, those on ventilators and those who have passed away is astounding. The numbers inform us about the severity of the problem and dictates a clarion call to find solutions to combat the pandemic, but numbers themselves don’t provide solutions nor provide a realistic roadmap to return to normalcy or at least, coexist with the ongoing threat of spread. Solutions need details… more

Laboratory Testing for SARS-CoV-2: Current Landscape and Lessons Learned

The Journal of Precision Medicine

The COVID-19 pandemic has accounted for more than 65 million infections and over 1.5 million deaths globally since first reported in December of 2019.1 The pandemic has dramatically disrupted individual lives and businesses leading to severe global health challenges and economic hardships. A vaccine(s) is on the near-term horizon for late 2020 or early 2021 for healthcare workers and those at high risk, but today virus spread is primarily being managed through public health measures such as social distancing, use of masks, and broad-scale testing programs… more

19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium

October 01, 2020 08:00 AM Eastern Daylight Time

Widespread accurate testing for SARS-CoV-2, the virus that causes COVID-19, is one critical aspect needed to limit the spread of the disease. By creating the COVID-19 Testing Industry Consortium, 19 organizations from the healthcare industry have joined forces with a goal to help inform, improve, innovate and accelerate various aspects of testing, ranging from research to clinical diagnostic applications.

The consortium brings together a diverse group of companies with synergistic areas of expertise, including precision medicine, diagnostics, occupational health, pharmaceuticals and clinical testing laboratories, to help provide clarity and potential solutions to COVID-19 testing challenges. To advance the goals of the consortium, members may:

  • Share relevant expertise, materials and experiences to accelerate understanding of COVID-19.
  • Analyze available scientific and health data, materials and information to develop, improve and deploy current assays and new approaches for the COVID-19 testing paradigm.
  • Contribute knowledge gained from the collaborative research by publishing work that will inform the scientific community and general public of the consortium’s findings.
  • The consortium was organized and is led by Bristol Myers Squibb. Consortium members include:
    • Alnylam Pharmaceuticals, Inc.
    • ArcherDx, Inc.
    • Biocartis NV
    • Color
    • Diaceutics, PLC
    • DxTerity Diagnostics, Inc.
    • Genosity, Inc.
    • Hematogenix Laboratory Services
    • Infinity BiologiX
    • Interpace Pharma Solutions, Inc.
    • Janssen Pharmaceuticals, NV
    • LabCorp
    • NeoGenomics Laboratories, Inc.
    • Novartis Institute for BioMedical Research
    • Ortho-Clinical Diagnostics, Inc.
    • Syngene International Limited
    • Takeda Pharmaceutical Company Limited (“Takeda”)
“In the three decades devoted to clinical diagnostics, I have been continually amazed that both the complexity and underlying value of testing is been markedly underappreciated. While the unprecedented challenges of the SARS-Covid-2 pandemic have focused a spotlight on the value, there remains a tendency to oversimplify testing. The COVID-19 Testing Consortium has brought together industry expertise to take on the challenge of addressing the details and intricacies that must be resolved if we are to find a holistic solution to both save lives, limit harm and bring life to some semblance of normalcy,” said Marc Grodman M.D. CEO of Genosity Inc. and former Chair of the American Clinical Laboratory Association. “We are proud to be part of a group with the collective knowledge and commitment to make a difference in this time of uncertainty and commend Bristol Myers Squib for their leadership in this effort.”

COVID-19 Company Update

March 20, 2020 08:00 AM Eastern Daylight Time

Genosity is actively monitoring the situation and taking the necessary steps to address the challenges created by the Coronavirus/COVID-19 pandemic and associated restrictions imposed on both individuals and organizations. Our primary goals are to protect the safety of our staff as well as ensure continuity and quality of the services we provide to our clients. We have had contingencies in place under our business continuity plan where safeguards and risk mitigating strategies have been enacted to protect the well-being of our employees, customers, suppliers and other stakeholders impacted by this pandemic. At this time, all of our staff members who can work remotely will work from home until further notice to support our laboratory and software services, so that our clients can continue to access our services without interruption or delay.  All essential employees continue to arrive to our laboratory facility. Visitation to our facility is limited to critical visitors who are subject to a prescribed screening program to reduce exposure of our essential laboratory staff. We are closely monitoring the situation and will provide updates if anything changes. If you have any specific questions, please reach out to your Genosity project manager or email us at As always, thank you for being our partner and for your continued trust and support as we work through these challenging times together.